MedTrace Logo

Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir

NCT07448844 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-07

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the nail) warts. The main questions it aims to answer are:

1. Does intralesional acyclovir or vitamin D3 lead to complete clearance of warts by week 8?
2. Which treatment clears warts more effectively?
3. What side effects do participants have with each treatment?

Researchers will compare acyclovir injections (Group A) to vitamin D3 injections (Group B), with 20 participants in each group, to see which treatment works better at clearing warts.

Participants will:

1. Receive an injection directly into the wart every 2 weeks for up to 4 sessions
2. Have photographs taken of their warts before treatment and at each visit
3. Visit the clinic for checkups where the size and number of warts will be measured
4. Be followed for up to 3 months to check for wart recurrence and side effects

Conditions

  • Viral Wart
  • Plantar Wart
  • Common Warts (Verruca Vulgaris)
  • Common Wart
  • Flat Wart
  • Warts of Foot
  • Warts Hand
  • Wart

Interventions

DRUG

Intralesional Acyclovir

Acyclovir (70 mg/mL) prepared by reconstituting a 250 mg vial with 3.5 mL of distilled water, injected directly into the wart lesion. Dosing is based on lesion size: 0.2 mL for warts ≤0.5 cm, 0.3-0.5 mL for 0.5-1 cm, and 0.5-1 mL for 1-1.5 cm. Administered at baseline and every 2 weeks for up to four sessions.

DRUG

Intralesional Vitamin D3

Vitamin D3 (200,000 IU; 5 mg/mL) injected directly into the wart lesion. Dosing is based on lesion size: 0.2 mL for warts ≤0.5 cm, 0.3-0.5 mL for 0.5-1 cm, and 0.5-1 mL for 1-1.5 cm. Administered at baseline and every 2 weeks for up to four sessions.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Fatima Sajid, FCPS · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-20
Primary Completion
2026-09-20
Completion
2026-09-20

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07448844 on ClinicalTrials.gov